Drugs / IBI939
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04672369 | Jun 2021 → Jan 2023 | lung cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04672356 | Jan 2021 → Jan 2023 | lung cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04353830 | May 2020 → May 2022 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-06-04 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting innoventbio.com ↗
The study results were as follows: |
| 2022-12-09 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress innoventbio.com ↗
Baseline characteristics: in the experimental arm (n=28), median age was 65 and 7 (25%) patients have brain metastasis; in the control arm (n=14), median age was 58 and 1 (7.1%) patient has brain metastasis. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-04 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Updates Phase 1b Data of IBI939 (Anti-TIGIT Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-selected NSCLC at the 2023 ASCO Annual Meeting innoventbio.com ↗ |
| 2022-12-09 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Presents Phase Ib Clinical Data of IBI939 (Anti-TIGIT Monoclonal Antibody) in Previously Untreated PD-L1-selected NSCLC at the 2022 European Society For Medical Oncology Immuno-Oncology Congress innoventbio.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI939 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04353830 ↗ |
| Known as | Tamgiblimab | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650473 ↗ |
| Action | Inhibit | “anti-TIGIT antibody” NCT04672369 ↗ |
| Modality | Protein / enzyme biologic | “recombinant fully human anti-TIGIT antibody (IBI939)” NCT04672369 ↗ |
| Route | Intravenous | “IBI939 will be given via intravenous (IV) infusion” NCT04353830 ↗ |
| Target | TIGIT | “anti-TIGIT antibody” NCT04672356 ↗ |